Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
Article 2021 en
Authors
FV
Fabrizio Vernieri
NB
Nicoletta Brunelli
RM
Roberta Messina
Abstract
1 min read
Migraine frequency and disability gradually increased after mAbs anti-CGRP interruption. Most patients did not relapse to MO or CM despite the increase in MMDs. Our data suggest to reconsider mAbs anti-CGRP discontinuation.
Iñaki Ochandiano, S. Salmerón, Helena Andreu, Luis Olivier, Òscar de Juan, Tabatha Fernández‐Plaza, Lluc Colomer, R Borras, Marc Valentí, Michael Berk, Ana C. Andreazza, Eduard Vieta, Anna Giménez‐Palomo, Isabella Pacchiarotti
Discussion(0)
No comments yet. Be the first to comment.